Zinc Supplementation and Severe and Recurrent Diarrhea

Diarrhea Clinical Trial

Official title:

Evaluating the Impact of 3 Months Daily Zinc Supplementation on Incidence of Severe and Recurrent Diarrhea in 6 to 36 Months Age Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01306097
• Other study ID #: Zinc supplementation
• Status: Completed
• Phase: N/A
• First received: February 28, 2011
• Last updated: February 28, 2011
• Start date: January 2009
• Est. completion date: May 2010

Study information

• Verified date: January 2009
• Source: Hormozgan University of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: Iran: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Evaluating the impact of 3 months daily zinc supplementation on incidence of severe and recurrent diarrhea in 6 to 36 months age children in Bandarabbaas

Description:

Evaluating the impact of 3 months daily zinc supplementation on incidence of severe and recurrent diarrhea in 6 to 36 months age children in Bandarabbaas in 2009

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: May 2010
• Est. primary completion date: January 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 6 Months to 36 Months

Eligibility

Inclusion Criteria:

• All 6 to 36 months old children without diarrhea at the time of study and without disease such as celiac

• Inflammatory bowl disease and hypersensitivity to milk

Exclusion Criteria:

• Diarrhea at the time of the study and background disease such as celiac, IBD or hypersensitivity to milk

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Diarrhea

Intervention

Drug:
• Zinc Supplement
10mg daily for under 1 years old children and 20mg daily for above 1 years old children

Locations

Country	Name	City	State
Iran, Islamic Republic of	Hormozgan University of medical sciences	Bandar Abbas	Hormozgan

Sponsors (1)

Lead Sponsor	Collaborator
Hormozgan University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diarrhea	Incidence, Duration and frequency	1 years	No
Secondary	Admission for diarrhea	Total number of admissions during the study period	1 year	No